MedTrace Logo

Study Evaluating Etanercept on Skin and Joint Disease in Psoriatic Arthritis

NCT00245960 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 752

Last updated 2022-01-31

Study results available
· View outcomes & findings →

Summary

The purpose of the study was to compare the efficacy of 2 different Etanercept regimens for the treatment of skin and joint manifestations of psoriatic arthritis.

Conditions

Interventions

DRUG

etanercept

DRUG

etanercept

DRUG

Placebo

Sponsors & Collaborators

  • Wyeth is now a wholly owned subsidiary of Pfizer

    lead INDUSTRY

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-12-27
Primary Completion
2008-03-29
Completion
2008-03-29

Countries

  • Argentina
  • Australia
  • Austria
  • Belgium
  • Colombia
  • Czechia
  • Denmark
  • Finland
  • France
  • Germany
  • Greece
  • Hungary
  • Italy
  • Mexico
  • Netherlands
  • Poland
  • Portugal
  • Saudi Arabia
  • Serbia and Montenegro
  • South Korea
  • Spain
  • Sweden
  • Switzerland
  • Taiwan
  • Turkey (Türkiye)
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00245960 on ClinicalTrials.gov